Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKZ | Q13574 | 10/20 | 0.38 |
| ▸ | DGKA | P23743 | 9/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26944424 | 0.86 | TACR1 (0.38) | DGKZDGKADPP8DPP4MAPK14 | |
| SCHEMBL26925710 | 0.86 | DPP8 (0.39) | DGKZDGKADPP8MAPK14SLC6A9 | |
| SCHEMBL21831875 | 0.86 | DPP8 (0.39) | DGKZDGKADPP8MAPK14SLC6A9 | |
| SCHEMBL21831052 | 0.86 | DPP8 (0.39) | DGKZDGKADPP8MAPK14SLC6A9 | |
| SCHEMBL26926184 | 0.85 | DGKZ (0.43) | DGKZDGKA | |
| SCHEMBL26932444 | 0.85 | DGKZ (0.43) | DGKZDGKA | |
| SCHEMBL21831325 | 0.85 | DGKA (0.43) | DGKZDGKADPP8 | |
| SCHEMBL26927649 | 0.85 | DGKZ (0.43) | DGKZDGKA | |
| SCHEMBL26927652 | 0.85 | DGKZ (0.43) | DGKZDGKA | |
| SCHEMBL26926180 | 0.85 | DGKZ (0.43) | DGKZDGKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023239768-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | INCYTE CORPORATION (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230399342-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | INCYTE CORPORATION | 2023-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399342-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | DGKA, DGKI, DGKG | DGKZ 6/4885DGKA 1/4885DPP8 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.